| Reduced indinavir exposure during pregnancy. | |
| | |
MedLine Citation:
|
PMID: 23305215 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
AIM: To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the postpartum period. METHODS: IMPAACT P1026s is an on-going, prospective, non-blinded study of antiretroviral pharmacokinetics (PK) in HIV-infected pregnant women with a Thai cohort receiving IDV/r 400/100 mg twice daily during pregnancy through 6-12 weeks postpartum as part of clinical care. Steady-state PK profiles were performed during the second (optional) and third trimesters and at 6-12 weeks postpartum. PK targets were the estimated 10(th) percentile IDV AUC (12.9 μg.h/mL) in non-pregnant historical Thai adults and a trough concentration of 0.1 μg/mL, the suggested minimum target. RESULTS: Twenty-six pregnant women were enrolled; thirteen entered during the second trimester. Median (range) age was 29.8 (18.9-40.8) years and weight 60.5 (50.0-85.0) kg at the third trimester PK visit. The 90% confidence limits for the geometric mean ratio of the indinavir AUC(0-12) and Cmax during the second trimester and postpartum (ante/post ratios) were 0.58 (0.49-0.68) and 0.73 (0.59-0.91), respectively; third trimester/postpartum AUC(0-12) and Cmax ratios were 0.60 (0.53-0.68) and 0.63 (0.55-0.72), respectively. IDV/r was well tolerated and 21/26 women had a HIV-1 viral load <40 copies/mL at delivery. All twenty-six infants were confirmed HIV negative. CONCLUSION: IDV exposure during the second and third trimesters was significantly reduced compared to postpartum and ∼30% of women fail to achieve a target trough concentration. Increasing the dose of IDV/r during pregnancy to 600/100 mg twice daily may be preferable to ensure adequate drug concentrations. |
| | |
Authors:
|
Tim R Cressey; Brookie M Best; Jullapong Achalapong; Alice Stek; Jiajia Wang; Nantasak Chotivanich; Prapap Yuthavisuthi; Pornnapa Suriyachai; Sinart Prommas; David E Shapiro; D Heather Watts; Elizabeth Smith; Edmund Capparelli; Regis Kreitchmann; Mark Mirochnick; |
Related Documents
:
|
19230785 - Treating non-tubal ectopic pregnancy. 7989505 - Refinements in the methodology of injection for transvaginal gamete intra-fallopian tra... 7657755 - Sterilization reversal: fertility results. 7254725 - Microsurgical reanastomosis of the fallopian tubes for reversal of sterilization. 17674275 - Correlation of the fetal cerebellar volume with other fetal growth indices by three-dim... 2899055 - Prenatal diagnosis of alpha-1-antitrypsin deficiency using oligonucleotide probe analysis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-11 |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: - ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2013 The Authors. British Journal of Clinical Pharmacology © 2013 The British Pharmacological Society. |
Affiliation:
|
Program for HIV Prevention and Treatment (IRD URI 174), Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang, Mai, Thailand; Harvard School of Public Health, Boston, MA, USA; Institut de Recherché pour le Développement (IRD), UMI 174-PHPT, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Method for isolation and molecular characterization of extracellular microvesicles released from bra...
Next Document: PINOCEMBRIN AND IT'S RAPIDLY EMERGING NEURO- PROTECTIVE EFFECTS COMMENT ON "Isolation and Identifica...